EarlySense is granted three US patents for contact-free, patient monitoring system capabilities: prediction of asthma, CHF and COPD exacerbation & the personalized patient deterioration predictor
EarlySense, the market leader in Proactive Patient Care Solutions, announced recently that the company has been granted three United States patents. The first, US Patent number 8,403,865, was granted for the ability of the EarlySense technology to monitor and predict congestive heart failure (CHF) and asthma attacks. The second US Patent, number 8,517,953 was granted for the technology’s ability to detect the sounds of wheezing or coughing and using these to monitor asthma, CHF or COPD patients. The third patent, 8,491,492, was granted for the technology’s personalized patient deterioration prediction and trend analysis capability. Inventors include: Dr. Zvika Shinar, Guy Meger, Dr. Daniel Lange, Yossi Gross, Avner Halperin and Itzhak Pinhas.
The EarlySense contact-free, patient safety monitoring solution is designed to help staff on the general care floors of hospitals identify the early warning signs of deterioration by monitoring heart, respiratory and motion parameters and empower clinical staff to proactively respond to avoid adverse events and secure better patient outcomes.
“The US patents announced today are a clear recognition of the value of our continuous efforts to innovate and develop uniquely valuable clinical solutions that empower clinicians to provide effective, proactive care. Personalizing the detection and prediction functions of algorithms is the wave of the future for hospital and long-term care, and eventually, home care,” said Avner Halperin, CEO of EarlySense and a company founder.
Mr. Halperin continued, “Using the personalization mechanisms, the EarlySense technology can detect changes in a patient’s condition and compare these to a learned personal baseline. Personalizing alarm mechanisms and thresholds is an important part of reducing false alarms, creating a quiet environment and improving outcomes. Importantly, this patented approach to reducing alarm fatigue is in line with the Joint Commission’s National Patient Safety Goal on Alarm Management. The Goal is intended to encourage hospitals to make alarm safety a higher priority and create a safer environment, free of patient injuries or deaths related to false alarms and alarm fatigue. The EarlySense technology helps clinicians to achieve this goal.”
EarlySense has brought to market an innovative technology designed to advance proactive patient care and empower clinicians to achieve better patient outcomes. Through early detection, the EarlySense system assists in identifying and preventing potential adverse events. It does so by providing motion rates and bed exit alarms, to reduce falls and pressure ulcers, as well as surveillance of heart and respiratory rates to potentially detect patient deterioration. The company’s flagship product, the EarlySense System, is a continuous, contact-free, patient safety monitoring solution that monitors and documents a patient’s vital signs and movement using a sensor that is placed underneath a bed mattress or a chair cushion. There are no leads or cuffs to connect to the patient who has complete freedom of movement and is not burdened by any cumbersome attachments. The system was designed to monitor patients on medical surgical floors who are usually monitored by nursing staff approximately once every four hours. The system is currently installed at hospitals and rehabilitation centers in the USA and Europe. It is also commercially available in Canada. Hospital administrators report that patients, their families and staff feel more comfortable knowing the system is in place. EarlySense Inc. is headquartered in Waltham, MA.